Transfusion-dependent Beta-Thalassemia Clinical Trial
Official title:
Long-term Follow-up of Subjects With Transfusion-Dependent β-Thalassemia (TDT) Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector
This is a multi-center, long-term safety and efficacy follow-up study for subjects with transfusion-dependent β-thalassemia (TDT) who have been treated with ex vivo gene therapy drug product in bluebird bio-sponsored parent clinical studies. After completing the parent clinical study (approximately 2 years), eligible subjects will be followed for an additional 13 years for a total of 15 years post-drug product infusion. No investigational drug product will be administered in this study.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04770779 -
A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)
|
Phase 3 | |
| Recruiting |
NCT05860595 -
Evaluation the Safety and Efficacy of KL003 Cell Injection in the Treatment of Transfusion-dependent β-thalassemia.
|
N/A | |
| Recruiting |
NCT05991336 -
Growth and Development-related Outcomes in Children With Transfusion-dependent Beta-thalassemia After Gene Therapy
|
||
| Not yet recruiting |
NCT06363760 -
A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301
|
||
| Recruiting |
NCT06219239 -
Safety and Efficacy of the Lentiviral Vector in Gene Therapy of Beta-thalassemia Patients
|
N/A | |
| Completed |
NCT06146478 -
Deciphering Effects of Thalidomide on Red Blood Cells in Transfusion Dependents Beta Thalassemia Patients
|
Phase 3 | |
| Not yet recruiting |
NCT06280378 -
A Phase I/II Clinical Study of the KL003 Cell Injection in β-Thalassemia Major Participants
|
Phase 1/Phase 2 |